In April, Abbott Laboratories announced it was yanking the FreeStyle InsuLinx blood glucose meters off the U.S. market, and now the FDA has assigned its most-serious Class I label to the effort, warning that the devices' malfunction could lead to serious injury or death.
Pfizer's spinoff of its animal health business into Zoetis is the biggest IPO this year. And the spinoff that created the newest Big Pharma company, AbbVie, was no slouch.
Abbott Laboratories has locked down European approval for a new diabetes diagnostic, getting the green light to market a test that can help diagnose and monitor diabetics as well as flag patients at risk for developing the disease.
Abbott Laboratories wanted to buy out its vaccine partner in Russia to better establish itself there. But the Russian government has not exactly thrown its arms open to Big Pharma and Abbott's hope has now been dashed on the hard wall of that reality.
Abbott Laboratories made a bid to acquire Russian vaccine outfit Petrovax, but the country's Federal Anti-Monopoly Service denied scuttled its plan.
Abbott Laboratories is working to reverse the fortunes of its lagging medical devices business, launching a now-FDA-approved eye implant for cataract patients.
Being the largest company by any number of measures--revenues, earnings, those kinds of yardsticks--is a good thing. Being the largest by number of employees is trickier, unless yours is also the largest by those other measures. As we have seen time and again in recent years in the pharma industry, having lots of employees and falling revenues is a formula that leads to layoffs. As a whole, the top 10 companies had fewer employees at the end of 2012 than at the end of 2011. Read the report >>
The new Abbott Laboratories is counting on med tech for revenue growth in a proprietary-drug-free future, and the company is so far succeeding in diagnostics while medical device sales falter.
Abbott's latest rollout of a new blood test involves a new CE marking for a diagnostic system to assess chronic heart failure patients.
Some Big Pharma heavyweights are duking it out for Brazil's Aché Laboratorios Farmaceuticos. Reuters sources say Pfizer, Novartis and Abbott Laboratories are in the fight, sizing up second-round bids in a deal worth around $5 billion.